Stock Traders Purchase High Volume of Editas Medicine Call Options (NASDAQ:EDIT)

Editas Medicine, Inc. (NASDAQ:EDIT) saw unusually large options trading on Wednesday. Stock traders purchased 2,160 call options on the stock. This represents an increase of approximately 245% compared to the typical daily volume of 626 call options.

Analyst Ratings Changes

Several analysts have recently commented on EDIT shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Editas Medicine in a report on Monday, April 20th. Chardan Capital increased their price objective on Editas Medicine from $3.50 to $4.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. TD Cowen reissued a “buy” rating on shares of Editas Medicine in a report on Wednesday. JonesTrading upgraded shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $8.00 target price on the stock in a research report on Tuesday, March 10th. Finally, Wall Street Zen downgraded shares of Editas Medicine from a “hold” rating to a “sell” rating in a report on Sunday, May 10th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $5.40.

Key Editas Medicine News

Here are the key news stories impacting Editas Medicine this week:

• Positive Sentiment: HC Wainwright and Zacks Research both raised near-term earnings estimates for Editas Medicine, with multiple quarters and full-year 2026/2027 forecasts moving modestly higher. That kind of analyst revision can help sentiment if investors believe costs are coming down faster than expected. Analyst estimate revisions for Editas Medicine
• Positive Sentiment: The stock also saw unusually heavy call-option activity and elevated trading volume, suggesting some investors are positioning for a move higher or increased volatility ahead of the company’s upcoming investor conference presentation. Updated investor conference presentation time
• Neutral Sentiment: Editas announced an updated presentation time for the 2026 Jefferies Global Healthcare Conference, where management may provide a fresh look at its pipeline and strategic priorities. On its own, this is mainly a calendar update, but it keeps the company visible to investors. Editas Medicine updated presentation announcement
• Neutral Sentiment: Short-interest data showed no meaningful change, so there is no clear evidence that a bearish squeeze or shift in short positioning is driving the stock today.
• Negative Sentiment: Despite the improved estimates, Editas is still expected to post losses across the forecast horizon, and its most recent quarter missed revenue expectations, underscoring that the business remains speculative and unprofitable.

Editas Medicine Stock Down 3.9%

Shares of NASDAQ:EDIT opened at $3.43 on Friday. Editas Medicine has a 52-week low of $1.66 and a 52-week high of $4.54. The stock’s fifty day simple moving average is $2.85 and its 200-day simple moving average is $2.43. The company has a market capitalization of $335.83 million, a P/E ratio of -2.79 and a beta of 2.14.

Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. Editas Medicine had a negative return on equity of 677.39% and a negative net margin of 281.59%.The firm had revenue of $2.83 million during the quarter, compared to analysts’ expectations of $6.37 million. On average, sell-side analysts anticipate that Editas Medicine will post -1.03 earnings per share for the current year.

Hedge Funds Weigh In On Editas Medicine

Institutional investors have recently modified their holdings of the company. Arete Wealth Advisors LLC purchased a new position in shares of Editas Medicine during the first quarter valued at approximately $88,000. Renaissance Technologies LLC grew its stake in Editas Medicine by 30.7% in the 1st quarter. Renaissance Technologies LLC now owns 3,972,160 shares of the company’s stock worth $9,811,000 after acquiring an additional 932,382 shares during the period. Sei Investments Co. raised its holdings in Editas Medicine by 19.6% in the 1st quarter. Sei Investments Co. now owns 88,707 shares of the company’s stock valued at $219,000 after acquiring an additional 14,516 shares during the last quarter. State of Wyoming purchased a new position in shares of Editas Medicine during the 1st quarter worth $43,000. Finally, Independent Financial Group LLC purchased a new position in shares of Editas Medicine during the 1st quarter worth $50,000. Institutional investors and hedge funds own 71.90% of the company’s stock.

Editas Medicine Company Profile

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.